BioSpace News Archive

Repair Biotechnologies, Inc. announced today that its lipid nanoparticle (LNP)/messenger RNA (mRNA) therapy has rapidly reversed the progression of atherosclerosis in mouse models applicable to both the rare genetic condition of familial hypercholesterolemia as well as atherosclerosis in the broader population.

Rancho Biosciences is excited to announce its work with the Davos Alzheimer’s Collaborative (DAC), a first-of-its-kind global public-private platform leading an unprecedented response to Alzheimer’s disease.

Edesa Biotech, Inc. announced today that Edesa management plans to participate in the following upcoming investor conferences.

Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration Implant, announced closing of a $20 million Series B extension financing round.

BostonGene to Present Cutting-Edge Research on Genomic and Transcriptomic Analysis for Cancer Patients.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announces its year-end 2023 update on operations following the filing of its audited Financial Statements and Management’s Discussion and Analysis for the year ended December 31, 2023.

Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd

Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), a leading healthcare technology company, will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

Nexalin Technology, Inc. today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William (“Bill”) A. Hudson, Jr., to the Company’s Military & Government Advisory Board (“Advisory Board”).

Inozyme Pharma, Inc today announced that Doug Treco, Ph.D., the company’s chief executive officer and chairman of the board, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024.